抗流感病毒药物研究进展  

Research progress of anti-influenza virus agents

作　　者：张强[1] 赵庆杰[1] 熊瑞生[1] 李剑峰[1] 沈敬山[1] 

机构地区：[1]中国科学院上海药物研究所,上海201203

出　　处：《药学学报》2010年第3期289-299,共11页Acta Pharmaceutica Sinica

基　　金：上海市科委国际科技合作基金资助项目(09540703900);国家科技部支撑计划资助项目(2006BAI01B02)

摘　　要：流感病毒是人类健康的一大威胁。应对流感病毒的主要方式是疫苗和药物治疗。对可能大规模爆发的流感疫情来讲,药物治疗是最好的控制流感病毒传播的手段。目前,抗流感病毒药物包括已在俄罗斯上市的盐酸阿比朵尔和美国FDA批准的4个抗流感病毒药物,后者根据作用机制的不同分为M2离子通道蛋白抑制剂和神经氨酸酶(NA)抑制剂。其中,NA抑制剂根据结构又可分为唾液酸类似物、苯甲酸衍生物、环己烯衍生物、环戊烷衍生物、吡咯烷衍生物及天然提取物6大类。本文简要介绍了上述各类已上市和临床在研药物的最新研究进展。Influenza is a major threat to millions of people worldwide. Vaccines and antiviral agents are two main options available to reduce the impact of the influenza virus, while anti-influenza agents are the most effective means to prevent the transmission of the highly contagious virus and to treat the epidemics of disease. At present, four anti-influenza agents have been approved by the FDA for the treatment of influenza, including two M2 protein ion channel inhibitors-amantadine and rimantadine and two neuraminidase inhibitors-zanamivir and oseltamivir. Arbidol hydrochloride, launched in Russia, is a potent inhibitor of influenza virus, too. Neuraminidase inhibitors could be classified generally by structure into six different kinds： sialic acid derivatives, benzoic acid derivatives, cyclohexene derivatives, cyclopentane derivatives, pyrrolidine derivatives and natural products. In this paper, recent progress in the research of the action mechanisms and structure-activity relationships of these anti-influenza virus agents were reviewed.

关 键 词：抗流感药物 M2离子通道蛋白抑制剂 盐酸阿比朵尔 神经氨酸酶抑制剂 

分 类 号：R916[医药卫生—药学]